Smoking cessation strategies in patients with COPD

European Respiratory Journal

Volumn 41, Issue 3, 2013, Pages 727-734

  Warnier, Miriam J ^a,b   Van Riet, Evelien E S ^a   Rutten, Frans H ^a   De Bruin, Marie Louise ^b   Sachs, Alfred P E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Behavioural therapy; Chronic obstructive pulmonary disease; Pharmacotherapy; Smoking cessation; Systematic review; Tobacco use cessation

Indexed keywords

AMFEBUTAMONE; NICOTINE; NORTRIPTYLINE; PLACEBO; VARENICLINE;

BEHAVIOR THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUNSELING; DRUG CHOICE; DRUG EFFICACY; HUMAN; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SMOKING CESSATION; SYSTEMATIC REVIEW; THERAPY EFFECT; TOBACCO DEPENDENCE;

BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84875241553     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00014012     Document Type: Review

References (57)

1. Fabbri LM, Hurd SS. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J 2003; 22: 1-2.
2. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-1648.
3. Wagena EJ, Zeegers MP, van Schayck CP, et al. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf 2003; 26: 381-403.
4. Shahab L, Jarvis MJ, Britton J, et al. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006; 61: 1043-1047.
5. Doll R, Hill AB. Smoking and carcinoma of the lung preliminary report. Br Med J 1950; 2: 739-748.
6. Falk JA, Kadiev S, Criner GJ, et al. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 543-548.
7. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009; 4: 337-349.
8. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-2075.
9. Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 334-342.
10. Godtfredsen NS, Vestbo J, Osler M, et al. Risk of hospital admission for COPD following smoking cessation and reduction: A Danish population study. Thorax 2002; 57: 967-972.
11. Kanner RE, Connett JE, Williams DE, et al. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: The Lung Health Study. Am J Med 1999; 106: 410-416.
12. Pauwels RA, Buist AS, Calverley PM. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
13. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
14. Burchfiel CM, Marcus EB, Curb JD, et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995; 151: 1778-1785.
15. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328: 1519-1519.
16. Anthonisen NR, Skeans MA, Wise RA. The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial. Ann Intern Med 2005; 142: 233-239.
17. Tonnesen P, Carrozzi L, Fagerstrom KO, et al. Smoking cessation in patients with respiratory diseases: A high priority, integral component of therapy. Eur Respir J 2007; 29: 390-417.
18. Tnnesen P, Carrozzi L, Fagerstrm KO, et al. Smoking cessation in patients with respiratory diseases: A high priority, integral component of therapy. Eur Respir J 2007; 29: 390-417.
19. Jimenez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: Differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365-1370.
20. Zhang MW, Ho RC, Cheung MW, et al. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: A systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry 2011; 33: 217-223.
21. van der Meer RM, Wagena EJ, Ostelo RW, et al. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003; 2: CD002999.
22. Wagena EJ, Arrindell WA, Wouters EF, et al. Are patients with COPD psychologically distressed? Eur Respir J 2005; 26: 242-248.
23. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990; 264: 1546-1549.
24. Wagena EJ, Van Der Meer RM, Ostelo RJ, et al. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: Results from a systematic review. Respir Med 2005; 1: 29-39.
25. Wagena EJ, Knipschild PG, Huibers MJ, et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 2286-2292.
26. Benowitz N. Nicotine addiction. N Engl J Med 2010; 362: 2295-2303.
27. Dilley J, Harris J, Boysun M, et al. Program, policy, and price interventions for tobacco control: Quantifying the return on investment of a state tobacco control program. Am J Public Health 2012; 102: E22-e28.
28. Nagelhout G, de Vries H, Fong G, et al. Pathways of change explaining the effect of smoke-free legislation on smoking cessation in the Netherlands. An Application of the international tobacco control conceptual model. Nicotine Tob Res 2012; [in press DOI: 10.1093/ntr/nts081].
29. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2011: Warning About the Dangers of Tobacco. Geneva, WHO, 2011.
30. Glanville JM, Lefebvre C, Miles JN, et al. How to identify randomized controlled trials in MEDLINE: Ten years on. J Med Libr Assoc 2006; 94: 130-136.
31. Wagena EJ, van der Meer RM, Ostelo RJ, et al. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: Results from a systematic review. Respir Med 2004; 98: 805-815.
32. Strassmann R, Bausch B, Spaar A, et al. Smoking cessation interventions in COPD: A network meta-analysis of randomised trials. Eur Respir J 2009; 34: 634-640.
33. McRobbie H, Lee M, Juniper Z. Non-nicotine pharmacotherapies for smoking cessation. Respir Med 2005; 99: 1203-1212.
34. Hoogendoorn M, Feenstra TL, Hoogenveen RT, et al. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 2010; 65: 711-718.
35. Hylkema MN, Sterk PJ, de Boer WI, et al. Tobacco use in relation to COPD and asthma. Eur Respir J 2007; 29: 438-445.
36. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998; 51: 1235-1241.
37. Wilson JS, Fitzsimons D, Bradbury I, et al. Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. Int J Nurs Stud 2008; 45: 508-517.
38. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial. Chest 2011; 139: 591-599.
39. Kotz D, Wesseling G, Huibers MJ, et al. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J 2009; 33: 754-762.
40. Kotz D, Wesseling G, Huibers MJ, et al. Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: Study protocol of a randomized controlled trial. BMC Public Health 2007; 7: 332.
41. Hilberink SR, Jacobs JE, Bottema BJ, et al. Smoking cessation in patients with COPD in daily general practice (SMOCC): Six months' results. Prev Med 2005; 41: 822-827.
42. Hilberink SR, Jacobs JE, Breteler MH, et al. General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: Impact after 1 year of two complex interventions. Patient Educ Couns 2011; 83: 120-124.
43. Christenhusz L, Pieterse M, Seydel E, et al. Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Educ Couns 2007; 66: 162-166.
44. Christenhusz LCA. Smoking Cessation in COPD Patients: (Cost-) Effectiveness of the Smokestoptherapy and Validation of Abstinence. PhD thesis, University of Twente, 2006.
45. Borglykke A, Pisinger C, Jorgensen T, et al. The effectiveness of smoking cessation groups offered to hospitalised patients with symptoms of exacerbations of chronic obstructive pulmonary disease (COPD). Clin Respir J 2008; 2: 158-165.
46. Pauwels RA, Buist AS, Ma P. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): Executive summary. Respir Care 2001; 46: 798-825.
47. Celli BR. ATS standards for the optimal management of chronic obstructive pulmonary disease. Respirology 1997; 2: Suppl. 1, S1-S4.
48. Gruffydd Jones K, Loveridge C. The 2010 NICE COPD Guidelines: How do they compare with the GOLD guidelines? Prim Care Respir J 2011; 20: 199-204.
49. Tashkin DP, Rennard S, Hays JT. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial. Chest 2011; 139: 591-599.
50. Hilberink SR, Jacobs JE, Bottema BJAM, et al. Smoking cessation in patients with COPD in daily general practice (SMOCC): Six months' results. Prev Med 2005; 41: 822-827.
51. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008; 4: CD006103.
52. Wu P, Wilson K, Dimoulas P, et al. Effectiveness of smoking cessation therapies: A systematic review and meta-analysis. BMC Public Health 2006; 6: 300.
53. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 1: CD000031.
54. Shah SD, Wilken LA, Winkler SR, et al. Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc (2003) 2008; 48: 659-665.
55. Schulz K, Altman D, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. Int J Surg 2011; 9: 672-677.
56. West R, Hajek P, Stead L, et al. Outcome criteria in smoking cessation trials: Proposal for a common standard. Addiction 2005; 100: 299-303.
57. Rovers M, Glasziou P, Appelman C, et al. Antibiotics for acute otitis media: A meta-analysis with individual patient data. Lancet 2006; 368: 1429-1435.